$BLCM Mainz Biomed 150 sites matters to me because it screams real world diversity, different clinics different workflows different patient mixes, that is how you build data that travels, not a narrow perfect lab sample, pair that with 15,000 subjects and this starts looking like a serious US pathway story while the company is still only about 8.85M cap at 1.03, PT 14 is +1,328.57% 🔥
$BLCM Bellicum Pharmaceuticals, Inc. (BLCM): A Promising Biotech Facing Challenges, But Exploring Strategic Alternatives to Unlock Value https://beyondspx.com/article/bellicum-pharmaceuticals-inc-blcm-a-promising-biotech-facing-challenges-but-exploring-strategic-alternatives-to-unlock-value
$BLCM Bellicum Pharmaceuticals, Inc. (BLCM): A Promising Biotech Facing Challenges, But Exploring Strategic Alternatives to Unlock Value http://beyondspx.com/2024/08/05/bellicum-pharmaceuticals-inc-blcm-a-promising-biotech-facing-challenges-but-exploring-strategic-alternatives-to-unlock-value/
$BLCM If you were in this, it was an investor's nightmare, but the caspase switch they had will be used by MD Anderson and licensed non-exclusively to other indications. This is, at least, a good outcome for patients. https://endpts.com/md-anderson-buys-tech-from-bellicum-tarsus-lyme-disease-trial-data-rigel-takes-gavreto/
